Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects

NCT06074107 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

128

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory Diffuse Large B-cell Lymphoma

Interventions

DRUG: BEBT-908 for injection

Sponsor

BeBetter Med Inc